GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce the DEA has Rescheduled EPIDIOLEX (cannabidiol) Oral Solution to Schedule V
GW Pharmaceuticals Announces Preliminary Results of Phase 2a Study for its Pipeline Compound GWP42006
Blue Lagoon Secures $2 Million Line of Credit from Nicola Mining Enhancing Financial Flexibility Ahead of Production
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements
